National Research Corporation Announces First Quarter 2022 Results
LINCOLN, Neb., May 03, 2022 (GLOBE NEWSWIRE) -- National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2022.
Q1 2022 financial results compared to Q1 2021:
- Revenue increased 8% to $38.4 million
- Operating income decreased 3% to $11.7 million
In commenting on recent events, Michael Hays, Chief Executive Officer, said “At year-end 2021, we announced the upcoming launch of NRC’s Health’s Human Understanding Program which enables health systems to deliver personalized care at scale. This past quarter, large numbers of current and prospective clients previewed and scrutinized the program. Never have I witnessed such absolute alignment with any product offering, confirming to me we are definitely on the right path. However, achieving personalized care at scale will not be instantaneous for any client organization; rather, accomplished by measured deployment of the Program over time and perhaps, similar to adoption trends we experienced with our digital Voice of the Customer offerings.
Regarding the Company’s first quarter financial performance, Kevin Karas, Chief Financial Officer, said, “Our growth strategy continues to focus on organic growth levers of increasing revenue from our core offerings, including our new Human Understanding Program, within our existing client base, as well as adding new clients to increase market share. As a result, revenue growth for the quarter was 8% over the prior year and we continued to see higher growth rates in our core offerings. Our operating expenses for the quarter increased at a higher rate as we allocated more resources towards innovation initiatives and associate empowerment benefits. We also utilized our strong cash flow to fund our quarterly dividend and additional share repurchases in the first quarter.”
Revenue for the first quarter ended March 31, 2022, was $38.4 million, compared to $35.5 million for the same quarter in 2021. Net income for the quarter ended March 31, 2022, was $8.5 million, compared to $9.2 million for the quarter ended March 31, 2021.
Diluted earnings per share decreased to $0.34 for the quarter ended March 31, 2022, from diluted earnings per share of $0.36 for the quarter ended March 31, 2021.
Cash Flow from Operations was $8.3 million down from $14.4 million, leaving us with a Net Cash position (Cash minus Notes Payable) of $21.8 million, up from $13.8 million at March 31, 2021.
A live simulcast of National Research Corporation’s 2022 first quarter conference call will be available online at https://events.q4inc.com/attendee/864665437 on May 4, 2022, beginning at 11:00 a.m. Eastern time. The online replay will follow approximately one hour later and continue for 30 days.
For more than 40 years, National Research Corporation has been a leading provider of analytics and insights that facilitate measurement and improvement to increase patient engagement and customer loyalty for healthcare providers, payers and other healthcare organizations in the United States and Canada. Our purpose is to enable human understanding by helping our clients to understand what matters most to each person that they serve.
This press release contains certain statements that may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended. Such statements may be identified by their use of terms or phrases such as “believes,” “expect,” derivations thereof, and similar terms and phrases. Forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause future events and actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements, including those risks and uncertainties as set forth in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2021 and various disclosures in our press releases, stockholder reports, and other filings with the Securities and Exchange Commission. We disclaim any obligation to update or revise any forward-looking statements to reflect actual results or changes in the factors affecting the forward-looking information.
NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Condensed Consolidated Statements of Income
(In thousands, except per share data)
| Three months ended|
|Selling, general and administrative||10,649||9,520|
|Depreciation, amortization and impairment||1,316||1,984|
|Total operating expenses||26,744||23,444|
|Other income (expense):|
|Total other income (expense)||(264||)||(408||)|
|Income before income taxes||11,433||11,612|
|Income tax provision (benefit)||2,894||2,380|
|Earnings Per Share of Common Stock:|
|Basic Earnings Per Share||$||0.34||$||0.36|
|Diluted Earnings Per Share||$||0.34||$||0.36|
|Weighted average shares and share equivalents outstanding|
NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Condensed Consolidated Balance Sheets
(Dollars in thousands, except share amounts and par value)
|March 31,||December 31,|
|Cash and cash equivalents||$||47,290||$||54,361|
|Accounts receivable, net||15,910||13,728|
|Other current assets||5,721||5,618|
|Total current assets||68,921||73,707|
|Property and equipment, net||12,853||12,391|
|Liabilities and Shareholders’ Equity|
|Current portion of notes payable, net unamortized debt issuance costs||$||4,333||$||4,278|
|Accounts payable and accrued expenses||4,675||7,393|
|Other current liabilities||3,886||1,321|
|Total current liabilities||41,569||40,388|
|Notes payable, net of current portion and unamortized debt issuance costs||21,161||22,269|
|Other non-current liabilities||8,938||9,546|
|Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued||--||--|
|Common stock, $0.001 par value; authorized 110,000,000 shares, issued|
30,898,600 in 2022 and 2021, outstanding 25,194,447 in 2022 and 25,361,409 in 2021
|Additional paid-in capital||174,227||173,942|
|Retained earnings (accumulated deficit)||(33,620||)||(36,112||)|
|Accumulated other comprehensive loss, foreign currency translation adjustment||(2,324||)||(2,375||)|
|Total shareholders’ equity||81,486||85,337|
|Total liabilities and shareholders’ equity||$||153,154||$||157,540|
|Contact:||Kevin R. Karas |
Chief Financial Officer
- Press release Biocartis Group NV: New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ GeneFusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods
- New Approach for Nose Job Without Breaking Bones
- Pennant Announces First Quarter 2022 Earnings Release and Call